Compounds and compositions as protein kinase inhibitors
US7449582B2 · kind B2 · utility
14Cited by
5References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 8, 2004 |
| Grant date | Nov 11, 2008 |
| Priority date | — |
| Expiry date | Jan 25, 2026 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, CSK, JNK1, JNK2, PDGF-R, p38, p70S6K, TGFβ, SRC, EGFR, c-Kit, trkB, FGFR3, Fes, Lck, Syk, RAF, MKK4, MKK6 and SAPK2β kinases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.